子宫内膜癌(Endometrial cancer,EC)在全球范围内是女性中第六位最常见的恶性肿瘤,其发病率呈现逐年上升的趋势。虽然早期子宫内膜癌患者的预后相对较好,但对于原发性晚期或复发性子宫内膜癌患者而言,中位总生存期往往不超过三年。目前,根据遗传突变信息,子宫内膜癌被划分为四种亚型:POLE超突变型、高微卫星不稳定性型...
^Sanchez-Lorenzo L, Sancho L, Iscar T, Grisham R, Chiva L. Management challenges in low-grade serous ovarian cancer with a BRCA mutation. Int J Gynecol Cancer. 2024 Apr 1;34(4):631-636. doi: 10.1136/ijgc-2023-005240. PMID: 38561200....
Herein we demonstrate that outcomes may vary dependent on variant allelic frequency (VAF) of TP53 missense mutations, not just the presence of a mutation alone. Methods: De-identified clinical data from the TCGA endometrial cancer cohort was obtained via cbioportal.org. Only patients with ...
Molecular precursor lesions in oesophageal cancer. Cancer Surv 1998; 32:53–68). PubMed CAS Google Scholar Jia L, Liu Y, Yi X et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin ...
Liu Z, Wan G, Heaphy C, et al (2007) A novel loss-of-function mutation in tp53 in an endometrial cancer cell line and uterine papillary serous carcinoma model. Mol Cell Biochem 297(297):179–187Liu Z, Wan G, Heaphy C, Bisoffi M, Griffith JK, Hu CA (2007) A novel loss-of-...
A novel loss-of-function mutation in TP53 in an endometrial cancer cell line and uterine papillary serous carcinoma model The etiology of carcinoma of the uterine endometrium (ECa) is poorly understood. However, loss of apoptosis is one of the major factors that allow cancer c... Z Liu,G ...
Preponderance of endometrial carcinoma in elderly patients Mol Clin Oncol, 9 (2018), pp. 269-273 PubMed PMID: 30155248; PMCID 6109667 Google Scholar 5 KC Kurnit, GN Kim, BM Fellman, et al. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at incr...
TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimized immunohistochemistry (IHC) for TP53 has been established as a proxy for the TP53 mutation status in other ovarian tumor
As 490% of TP53 mutations are localized in the core domain of the protein (residue 100 to 300), all p53 protein isoforms are affected by these alterations.19 The distribution of mutations in the p53 protein is also unique among all cancer genes, including oncogenes and Figure 1 Mutation ...
Selinexor combined regimen for treatment of triple-expressor elderly intermediate or high risk relapsed/refractory diffuse large B-cell lymphoma with TP53 mutation: report of 1 case and review of literature Fu Haiying Qiu Chenxi Chen Ningning Wang He Liu Limin Chen Xuzheng Xu Liping Liu...